Targeted drug delivery for treating nervous system disorders like ALS
Multimeric Peptide Copolymer Formulations for Targeted Drug Delivery to Treat Nervous System Disorders
This study is exploring new ways to help deliver medications directly to the nervous system for people with ALS, aiming to find better treatments that could slow down the disease and improve daily life.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-10833041 on NIH RePORTER |
What this research studies
This research focuses on developing innovative formulations using multimeric peptide copolymers to enhance drug delivery specifically to the nervous system. By utilizing a unique bacteriophage biopanning strategy, the researchers aim to identify peptides that can effectively transport therapeutic agents across the blood-brain barrier, which is a significant challenge in treating conditions like amyotrophic lateral sclerosis (ALS). The approach involves targeting neurons directly to improve the efficacy of treatments that have shown promise in pre-clinical studies. Patients may benefit from more effective therapies that could slow disease progression and improve quality of life.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with amyotrophic lateral sclerosis (ALS) or other related nervous system disorders.
Not a fit: Patients with conditions unrelated to nervous system disorders or those who are not diagnosed with ALS may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for ALS and other nervous system disorders, potentially improving patient outcomes and extending survival.
How similar studies have performed: Previous research has shown promise in using targeted delivery methods for neurological conditions, indicating potential success for this novel approach.
Where this research is happening
Seattle, United States
- University of Washington — Seattle, United States (Active)
Researchers
- Principal investigator: Sellers, Drew L — University of Washington
- Study coordinator: Sellers, Drew L
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.